Abstract
A prospective, randomised, open trial was performed in 150 patients to test for any beneficial effects on 2-year mortality of long-term antiarrhythmic therapy with phenytoin in patients with acute myocardial infarction. Patients were stratified according to age, sex, past history of myocardial infarction, and the presence of absence of electrical or mechanical complications in the course of acute infarction. They were then randomised to treatment or control groups (74 v. 76). The former received phenytoin in doses aimed at maintaining plasma phenytoin levels between 40 and 80 mumol/litre. All patients entered the study before discharge from the coronary care ward. Plasma phenytoin levels were in the therapeutic range in between 51 and 75 per cent of subjects at any follow up visit. There were 19 withdrawals from the treatment group, 10 of which were the result of side effects. There were 5 withdrawals from the control group. According to the original intention to treat, there were 18 deaths at 2 years in the treatment group and 14 deaths in the control group. There was no reduction in the incidence of instantaneous or sudden deaths. Deaths on treatment were not associated with a low phenytoin plasma level. Phenytoin treatment showed no beneficial effects on mortality and was associated with a high incidence of side effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ahlmark G., Saetre H., Korsgren M. Letter: Reduction of sudden Deaths after myocardial infarction. Lancet. 1974 Dec 28;2(7896):1563–1563. doi: 10.1016/s0140-6736(74)90299-2. [DOI] [PubMed] [Google Scholar]
- Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121–134. doi: 10.1002/cpt1970111121. [DOI] [PubMed] [Google Scholar]
- Bigger J. T., Jr, Schmidt D. H., Kutt H. Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects. Circulation. 1968 Aug;38(2):363–374. doi: 10.1161/01.cir.38.2.363. [DOI] [PubMed] [Google Scholar]
- Kosowsky B. D., Taylor J., Lown B., Ritchie R. F. Long-term use of procaine amide following acute myocardial infarction. Circulation. 1973 Jun;47(6):1204–1210. doi: 10.1161/01.cir.47.6.1204. [DOI] [PubMed] [Google Scholar]
- Perrier D., Rapp R., Young B., Kostenbauder H., Cady W., Pancorbo S., Hackman J. Maintenance of therapeutic phenytoin plasma levels via intramuscular administration. Ann Intern Med. 1976 Sep;85(3):318–321. doi: 10.7326/0003-4819-85-3-318. [DOI] [PubMed] [Google Scholar]
- Reynolds J. L., Whitlock R. M. Effects of a beta-adrenergic receptor blocker in myocardial infarction treated for one year from onset. Br Heart J. 1972 Mar;34(3):252–259. doi: 10.1136/hrt.34.3.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wallace J. E. Microdetermination of diphenylhydantoin in biological specimens by ultraviolet spectrophotometry. Anal Chem. 1968 May;40(6):978–980. doi: 10.1021/ac60262a023. [DOI] [PubMed] [Google Scholar]
- Wilhelmsson C., Vedin J. A., Wilhelmsen L., Tibblin G., Werkö L. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet. 1974 Nov 16;2(7890):1157–1160. doi: 10.1016/s0140-6736(74)90807-1. [DOI] [PubMed] [Google Scholar]